MSDS Cryopreserved Cells
Instructions CnOb
Cell Apps Flyer Skeletal System Cells
5 Important Cell Culture Rules
Cell Apps Poster Primary Cells
Cell Applications Inc Brochure
Description
Canine Osteoblasts (CnOb) from Cell Applications, Inc. provide an excellent model system for studies relevant to the skeletal system, including mechanisms of cancerogenesis.
Our CnOb. have been used to:
- Define a biomarker profile of canine osteosarcoma, elucidate the roles of oncogenic STAT3 and canonical Wnt signaling pathways
- Develop personalized osteosarcoma treatments by testing Src inhibitor dasatinib, procaspase-3 activating compound PAC-1, HSP90 inhibitor STA‐1474 and STAT3 inhibitor LLL12.
Characterization: Positive for bone mineralization
(Click to Enlarge) Canine Osteoblasts, CnOb (L) von Kossa stained (R).
Details
Tissue | Normal healthy canine bone. |
QC | No bacteria, yeast, fungi, mycoplasma |
Character | Bone mineralization (von Kossa stain) |
Bioassay | Attach, spread, proliferate in Growth Med |
Cryovial | 500,000 CnOb (1st passage) frozen in Basal Medium w/ 10% FBS, 10% DMSO |
Kit | Cryovial frozen CnOb (Cn406-05), Growth Med (Cn417-500), Subcltr Rgnt Kit (090K) |
Proliferating | Shipped in Gr Med, 2nd psg (flasks or plates) |
Doublings | At least 10 |
Applications | Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use. |
Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| Cryopreserved Canine Osteoblast Total Kit: 5x10^5 Cells, Medium & Subculture Reagents (See Details tab for specifics) | Size: 1 Kit | CAT.#: Cn406K-05 | Price: $961.00 | |
| Cryopreserved Canine Osteoblasts (CnOb): Frozen CnOb (5x10^5) | Size: 1 Cryovial | CAT.#: Cn406-05 | Price: $775.00 | |
| Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium | Size: T-25 Flask | CAT.#: Cn407-25 | Price: $775.00 | |
| Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium | Size: T-75 Flask | CAT.#: Cn407-75 | Price: $965.00 | |
| Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium | Size: 24 Well | CAT.#: Cn407-24W | Price: $965.00 | |
| Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium | Size: 96 Well | CAT.#: Cn407-96W | Price: $1,085.00 |
Related Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| CnOb Basal Medium: Basal medium (contains no growth supplement). Add GS before use. | Size: 500 ml | CAT.#: Cn416-500 | Price: $81.00 | |
| CnOb Growth Medium: All-in-one ready-to-use | Size: 500 ml | CAT.#: Cn417-500 | Price: $133.00 | |
| CnOb Growth Medium Kit: Basal medium & growth supplement sold together packaged separately | Size: Yields 500ml | CAT.#: Cn417K-500 | Price: $144.00 | |
| CnOb Differentiation Medium: Promotes cells to change from one type to another, more specialized | Size: 250 ml | CAT.#: Cn417D-250 | Price: $92.00 | |
| CnOb Growth Supplement: Added to Basal Medium to create Growth Medium | Size: 30 ml | CAT.#: Cn417-GS | Price: $81.00 |
Extended Family Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| Subculture Reagent Kit: 100 ml each of HBSS, Trypsin/EDTA & Trypsin Neutralizing Solution | Size: 1 Kit | CAT.#: 090K | Price: $63.00 |
Resources/Documents
Citations
Powered by BiozPublications
2017
Troyer RM, Ruby CE, Goodall CP, Yang L, Maier CS, Albarqi HA, Brady JV, Bathke K, Taratula O, Mourich D, Bracha S. 2017. Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Exp Cell Res. pii: S0014-4827(17)30365-8.
Murahari, S., A. Jalkanen, S. ulp, C. Chen, J. Modiano, C. London and W. Kesseberth. 2017. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer, 17:67.
2016
Fenger, J., R. Roberts, O. Iwenofu, M. Bear, X. Zhang, J. Couto, J. Modiano, W. Wisseberth and C. London. 2016. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer, 16:784.
González-Miguel, J., C. Larrazabal, D. Loa-Mesón, M. Siles-Lucas, F. Simón and R. Morchón. 2016. Glyceraldehyde 3-phosphate dehydrogenase and galectin from Dirofilaria immitis participate in heartworm disease endarteritis via plasminogen/plasmin system. Veterinary Parasitology, 223:96-101.
2015
de Sá Rodrigues, L., K. Holmes, V. Thompson, C. Piskun, S. Lana, M. Newton and T. Stein. 2015. Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns. DOI: 10.1111/vco.12132.
Fenger, J. 2015. Investigating the Biological and Molecular Consequences of MiR-9 Dysregulation in Canine Mast Cell Tumors and Osteosarcoma. PhD Dissertation, Ohio State University.
2014
Quintanilha, L., T. Takami, Y. Hirose, K. Fujisawa, Y. Murata, N. Yamamoto, R. Goldenberg, S. Terai and I Sakaida. 2014. Canine mesenchymal stem cells show antioxidant properties against thioacetamide-induced liver injury in vitro and in vivo. Hepatology Res, 44:E206-E217.
2013
Couto, J. 2013. Biologic Activity of the Novel Small Molecule STAT3 Inhibitor Against Canine Osteosarcoma Cell Lines. The Ohio State University, M.Sc. dissertation.
Davis, L.E., N.E. Hofmann, G. Li, E.T. Huang, M.M. Loriaux, S. Bracha, S.C. Helfand, J.E. Mata, K. Marley, and A. Mansoor. 2013. A case study of personalized therapy for osteosarcoma. Pediatric blood & cancer. 60:1313-1319.
Milovancev, M., I. Hilgart-Martiszus, M.J. McNamara, C.P. Goodall, B. Seguin, S. Bracha, and S.I. Wickramasekara. 2013. Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts. BMC veterinary research. 9:116.
Piskun, C.M., and T.J. Stein. 2013. β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour. Vet. & Comp. Oncology: doi: 10.1111/vco.12077.
2012
Book, A.P. 2012. Investigating procaspase-3 as a potential therapeutic target in canine osteosarcoma. Master of Science Thesis. University of Illinois.
Couto, J.I., M.D. Bear, J. Lin, M. Pennel, S.K. Kulp, W.C. Kisseberth, and C.A. London. 2012. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC veterinary research. 8:244.
2011
Fossey, S., M. Bear, W. Kisseberth, M. Pennell, and C. London. 2011. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC cancer. 11:125.
McCleese, J. 2011. Investigating the Biological and Biochemical Consequences of Met Function and Dysfunction in Canine Osteosarcoma. PhD Dissertation, The Ohio State University.
2010
Fossey, S. 2010. Characterization of STAT3 Activation in Osteosarcoma. PhD Dissertation, Ohio State University.
2009
Fossey, S.L., A.T. Liao, J.K. McCleese, M.D. Bear, J. Lin, P.-K. Li, W.C. Kisseberth, and C.A. London. 2009. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC cancer. 9:81.
McCleese, J.K., M.D. Bear, S.L. Fossey, R.M. Mihalek, K.P. Foley, W. Ying, J. Barsoum, and C.A. London. 2009. The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines. Int. J.Cancer. 125:2792-2801.